-
EP4277613
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4277613
| EP4277613 - PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 31.10.2025 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 20.10.2023 | ||
| Former | The international publication has been made Status updated on 22.07.2022 | Most recent event Tooltip | 27.02.2026 | Change: Despatch of examination report + time limit | Applicant(s) | For all designated states University of Tennessee Research Foundation 600 Henley Street Knoxville, TN 37996 / US | [2023/47] | Inventor(s) | 01 /
STEINER, Mitchell Germantown, Tennessee 38139 / US | 02 /
NARAYANAN, Ramesh Cordova, Tennessee 38018 / US | 03 /
AHN, Sunjoo Daejeon Daejeon 34061 / KR | 04 /
DALTON, James Ann Arbor, Michigan 48103 / US | [2023/47] | Representative(s) | Pearl Cohen UK The Gridiron Building One Pancras Square London N1C 4AG / GB | [N/P] |
| Former [2023/47] | Pearl Cohen Zedek Latzer Baratz UK LLP The Gridiron Building One Pancras Square London N1C 4AG / GB | Application number, filing date | 22740195.7 | 14.01.2022 | [2023/47] | WO2022US12631 | Priority number, date | US202117151108 | 15.01.2021 Original published format: US202117151108 | [2023/47] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022155543 | Date: | 21.07.2022 | Language: | EN | [2022/29] | Type: | A1 Application with search report | No.: | EP4277613 | Date: | 22.11.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.07.2022 takes the place of the publication of the European patent application. | [2023/47] | Search report(s) | International search report - published on: | US | 21.07.2022 | (Supplementary) European search report - dispatched on: | EP | 21.10.2024 | Classification | IPC: | A61K31/277, A61K31/167, A61K45/06, A61K31/506, A61K31/519, A61P35/00 | [2024/47] | CPC: |
A61K45/06 (EP,IL,KR);
A61K31/277 (EP,IL,KR);
A61K31/167 (KR);
A61K31/506 (EP,IL,KR);
A61K31/519 (EP,IL,KR);
A61P35/00 (EP,KR);
A61K2300/00 (IL,KR)
(-)
| C-Set: |
A61K31/277, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP)
|
| Former IPC [2023/47] | A61K31/167, A61K31/277, A61K35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/47] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON BRUSTKREBS UND VERFAHREN ZUR VERWENDUNG DAVON | [2023/47] | English: | PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF | [2023/47] | French: | COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE CANCERS DU SEIN ET LEURS MÉTHODES D'UTILISATION | [2023/47] | Entry into regional phase | 14.07.2023 | National basic fee paid | 14.07.2023 | Search fee paid | 14.07.2023 | Designation fee(s) paid | 14.07.2023 | Examination fee paid | Examination procedure | 14.07.2023 | Examination requested [2023/47] | 07.05.2025 | Amendment by applicant (claims and/or description) | 07.05.2025 | Date on which the examining division has become responsible | 30.10.2025 | Despatch of a communication from the examining division (Time limit: M06) | Fees paid | Renewal fee | 29.01.2024 | Renewal fee patent year 03 | 27.01.2025 | Renewal fee patent year 04 | 27.01.2026 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XIY] WO2020028593 (ONCTERNAL THERAPEUTICS INC et al.) [X] 1-5,10-11,14-15 * paragraphs [0064] , [ 254] , [ 255] , [ 260]; claim 1 *[I] 1-15 [Y] 1-15 | [XIY] US2017209407 (DALTON JAMES T et al.) [X] 1-5,10-11,14-15 * paragraphs [0086] - [0092] - [ 394] , [ 395] , [ 400]; claim 1 *[I] 1-15 [Y] 1-15 | [Y] WENFEI JI ET AL: "Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 15, no. 3, 1 January 2019 (2019-01-01), pages 522 - 532, XP055558235, ISSN: 1449-2288, DOI: 10.7150/ijbs.30572 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.7150/ijbs.30572 | [Y] LYONS TOMAS G ET AL: "Androgen Receptor-Targeted Therapy for Breast Cancer", CURRENT BREAST CANCER REPORTS, SPRINGER US, BOSTON, vol. 9, no. 4, 24 October 2017 (2017-10-24), pages 242 - 250, XP036367246, ISSN: 1943-4588, [retrieved on 20171024], DOI: 10.1007/S12609-017-0261-8 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1007/s12609-017-0261-8 | International search | [A] US2019111010 (NARAYANAN RAMESH et al.) [A] 1,2 * entire document * | [A] WO2017223115 (RADIUS HEALTH INC et al.) [A] 1,2 * entire document * | [A] US2007066568 (DALTON JAMES T et al.) [A] 1,2 * entire document * | Examination | HICKEY THERESA E. ET AL: "The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer", NATURE MEDICINE, vol. 27, no. 2, 18 January 2021 (2021-01-18), New York, pages 310 - 320, XP093321455, ISSN: 1078-8956, DOI: 10.1038/s41591-020-01168-7 [I] 1-15 [Y] 1-15 DOI: http://dx.doi.org/10.1038/s41591-020-01168-7 | HAFNER MARC ET AL: "Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 8, 6 June 2019 (2019-06-06), pages 1067, XP085774751, ISSN: 2451-9456, [retrieved on 20190606], DOI: 10.1016/J.CHEMBIOL.2019.05.005 [I] 1-15 [Y] 1-15 DOI: http://dx.doi.org/10.1016/j.chembiol.2019.05.005 |